The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas
Francis D, Dougan J, Pillsbury C, Park S, Langermann S, Koff J, Li Z, Flowers C, Porter C. The Immune Checkpoint Siglec-15 in Promoting Immune Dysregulation in Non-Hodgkin's Lymphomas. Blood 2023, 142: 4367. DOI: 10.1182/blood-2023-190405.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaB-cell lymphomaAggressive B-cell lymphomasGerminal center B cellsImmune responseBurkitt's lymphomaLymphoma casesDisease progressionSiglec-15Immune deficient (SCID) BALB/c miceR diffuse large B-cell lymphomaB cellsDeficient BALB/c miceLocal anti-tumour immune responseAggressive mature B-cell lymphomaAnti-tumor immune responseBALB/c miceLarge B-cell lymphomaHealthy donor PBMCsIntensive salvage regimensMost diffuse large B-cell lymphomasEvent-free survivalFirst-line treatmentRefractory hematologic malignanciesNon-Hodgkin lymphoma casesCharacterization of the HLA-F ligandome in T-cell lymphoma
Mota I, Osean J, Song E, Clement C, Lenz J, Miller D, Inghirami G, Montagna C, Bouvier M, Iwasaki A, Santambrogio L. Characterization of the HLA-F ligandome in T-cell lymphoma. The Journal Of Immunology 2023, 210: 222.06-222.06. DOI: 10.4049/jimmunol.210.supp.222.06.Peer-Reviewed Original ResearchT-cell lymphoma cell linesHealthy donor PBMCsT cellsLymphoma cell linesHLA-FDonor PBMCsTumor-specific antigensCancer immune responseT-cell lymphomaTotal T cellsNK cell receptorsTumor-specific markersCell linesHLA-I moleculesPeptides to T cellsCancer immunotherapyNK cellsHLA haplotypesRegulating immunityTherapeutic targetPotential new classDNA integrityDNA methylation patternsPeptide repertoirePBMC
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply